Patented turbo for immunotherapies against cancer

Production time for cell therapies reduced from weeks to days

09-Jul-2025 - Immune cells are becoming the weapon of choice increasingly in the fight against cancer. A Vienna-based research group has now patented new forms of cultivation that make particularly combative immune cells multiply much faster. Their vision: to quickly provide cancer patients with individualized ...

Severe Polyneuritis Successfully Treated with CAR T-Cell Therapy

"We are starting a new chapter in the treatment of severe autoimmune diseases"

20-Jun-2025 - A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare autoimmune disease of the peripheral nervous system. This treatment modifies endogenous immune cells such that they can specifically target and eliminate B lymphocytes, which ...

Tracking immune cells inside the body

New method for labeling T cells in immunotherapy

17-Jun-2025 - In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers at the Technical University of Munich (TUM) have developed a method for tracking these cells in the body. This new approach could deepen our understanding of cellular ...

Biotech startup acquires german subsidiary of Bristol Myers Squibb

Strategic acquisition to accelerate development of innovative cell therapies

02-Jun-2025 - TQ Therapeutics GmbH (“TQx”), a biotechnology company dedicated to advancing the field of cellular therapies through innovative technologies, announced the acquisition of Juno Therapeutics GmbH (“Juno GmbH”), a cell therapy company, through a share purchase agreement. Juno GmbH is a German ...

Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

23-May-2025 - Waters Corporation announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly ...

“We’re working at full force to put Bayer back on a profitable growth path”

Progress on strategic priorities

28-Apr-2025 - The Bayer Group made major progress in a number of areas in 2024 and is actively taking steps to tackle the serious challenges it faces. “We’re working hard to remove these obstacles and put Bayer back on a profitable growth path. We’re making excellent progress, but there’s still a lot to do,” ...

Engineering Smart Delivery for Gene Editors

Restoring Vision: New hope for genetic diseases and cancer therapies

11-Apr-2025 - A research team from Helmholtz Munich and the Technical University of Munich has developed an advanced delivery system that transports gene-editing tools based on the CRISPR/Cas9 gene-editing system into living cells with significantly greater efficiency than before. Their technology, ENVLPE, ...

Rare side effect discovered in cancer immunotherapy

25-Feb-2025 - Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The results of the study have been published by scientists from Leipzig University Hospital, the Fraunhofer Institute for Cell Therapy and Immunology and Cologne University ...

A new switch for the cell therapies of the future

A new gene switch can be activated using a commercially available nitroglycerine patch applied to the skin

18-Feb-2025 - The body regulates its metabolism precisely and continuously, with specialised cells in the pancreas constantly monitoring the amount of sugar in the blood, for example. When this blood sugar level increases after a meal, the body sets a signal cascade in motion in order to bring it back down. In ...

Stockholm-based biotech start-up aims to develop the next generation of cell therapies

Neogap Therapeutics' PIOR technology identifies targets for personalised liver cancer immunotherapies

17-Feb-2025 - A new study published in the scientific journal Gut examines how immune system T cells respond to tumours in patients with advanced liver cancer (HCC). Using Neogap Therapeutics' PIOR® software platform, the researchers have identified tumour-specific mutations, which may contribute to the ...